Tegoprazan
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Tegoprazan
- Molecular weight
- 387.39
- Structure (SMILES)
- Cc1nc2cc(C(=O)N(C)C)cc(O[C@H]3CCOc4cc(F)cc(F)c43)c2[nH]1
- bli5100
- BLI5100
- cj 12420
- Cj-12420
- CJ-12420
- CJ-12420 100 mg QD
- CJ-12420 100mg
- CJ-12420 100mg QD
- CJ-12420 200mg
- CJ-12420 50 mg QD
- CJ-12420 50mg
- CJ-12420 50mg QD
- IN-A001(Tegoprazan)
- lxi 15028
- Lxi-15028
- LXI-15028
- LXI-15028 100mg
- LXI-15028 200mg
- LXI-15028 50mg
- tegoprazan
- Tegoprazan
- Tegoprazan (C1)
- Tegoprazan (C2)
- Tegoprazan (C3)
- tegoprazan [INN]
And 14 more, listed on the interactive page.
- ATC classification codes
- A02BC09
Sources for recorded values
- CAS registry numbers
- 942195-55-3
- ChEMBL ID
- CHEMBL4297583
- InChIKey
- CLIQCDHNPDMGSL-HNNXBMFYSA-N
- PubChem compound IDs
- 23582846
- FDA ingredient codes (UNII)
- W017G7IF4S
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- tegoprazan
- Type
- Synthetic organic
- Drug name stem
- -prazan
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- Potassium-transporting ATPase blocker
- Action type
- Blocker
- Target
- Potassium-transporting ATPase
- Protein identifier
- P20648
- Mechanism
- Potassium-transporting ATPase blocker
- Action type
- Blocker
- Target
- Potassium-transporting ATPase
- Protein identifier
- P51164
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ATP4A
- Gene symbol
- ATP4A
- Protein identifier
- P20648
- Median affinity
- 6.28
- Affinity units
- pIC50
Open Targets mechanisms
- Mechanism
- Potassium-transporting ATPase blocker
- Action type
- Blocker
- Target
- Potassium-transporting ATPase
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Gastroesophageal Reflux
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003948
- Subject identifier
- D005764
- Condition
- Duodenal Ulcer
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004607
- Subject identifier
- D004381
- Condition
- Stomach Ulcer
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009454
- Subject identifier
- D013276
- Condition
- Helicobacter Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
- Condition
- Laryngopharyngeal Reflux
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001355
- Subject identifier
- D057045
- Condition
- Peptic Ulcer
- Highest recorded phase
- 3
- Condition identifier
- HP:0004398
- Subject identifier
- D010437
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003948
- Condition identifier
- EFO_0004607
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009454
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000961
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001355
- Highest recorded phase
- 3
- Condition identifier
- HP_0004398
- Condition identifier
- HP_0004398
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001126
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005412
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006781
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007186
- Highest recorded phase
- 4
- NCT02028663
- NCT02456935
- NCT02556021
- NCT02995239
- NCT03006874
- NCT03591653
- NCT03615677
- NCT04022096
- NCT04568772
- NCT02761512
- NCT04128917
- NCT05577468
- NCT05933031
- NCT04494269
- NCT04840550
- NCT05010954
- NCT05871398
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 67.45
- Calculated partition coefficient (ALogP)
- 3.75
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 28
- Molecular formula
- C20H19F2N3O3
- Monoisotopic mass
- 387.13944780
- Natural product
- No
- Recorded assays
- 18
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (73)
- A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
- A Phase 1 Study of Tegoprazan on Healthy Male Volunteers
- A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
- A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.
- A Phase I Study of LX22001 for Injection in Healthy Subjects
- A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
- A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
- A Study to Compare the Pharmacokinetic Characteristics of CJ-12420
- A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers
- A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
- A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
- A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
- A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn
- A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
- A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers
- Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia
- Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole
- Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）
- Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
In development for (6)
- Duodenal ulcer Phase 3
- Gastric ulcer Phase 3
- Gastroesophageal reflux disease Phase 3
- Helicobacter pylori infectious disease Phase 3
- Liver disorder Phase 1
- Peptic ulcer disease Phase 3